A synthetic version of the actin-sequestering peptide Thymosin Beta-4, recognized for its role in tissue repair, reduced inflammation, and enhanced cell migration.
Sourced from Ascension Peptides. Verified purity, third-party tested. COA included.
Buy Now →TB-500 is the common research designation for a synthetic fragment of thymosin beta-4 (Tβ4), one of the most ubiquitous and biologically active members of the beta-thymosin peptide family. The parent protein, thymosin beta-4, is a 43-amino acid peptide that was first isolated from calf thymus glands in the early 1970s by researchers at the National Cancer Institute, initially in the context of thymic hormone research aimed at understanding immune cell development. Over the following two decades, the research community recognized that Tβ4’s biological roles extended far beyond immunology into fundamental cellular processes governing cytoskeletal dynamics, cell migration, and tissue repair.
Thymosin beta-4 is remarkable in several respects. It is one of the most abundant intracellular peptides in most mammalian cell types, present at concentrations of 300–500 micromolar in platelets and various tissue compartments. Unlike classical hormones or neuropeptides that are produced by specialized secretory cells, Tβ4 is expressed constitutively in virtually every cell type that has been examined, suggesting its functions are fundamental to basic cell biology rather than specialized physiological signaling. Its primary intracellular role involves binding G-actin (globular, monomeric actin) to maintain the pool of unpolymerized actin available for rapid cytoskeletal remodeling during cell migration, division, and shape change.
TB-500 specifically refers to the actin-binding tetrapeptide domain of thymosin beta-4 — the sequence Ac-LKKTETQ (in some formulations extended to include the central actin-binding motif LKKTETQEKNTPKSA, residues 17–23 of the full protein) — though commercial research preparations sold under the TB-500 designation are typically synthetic analogs of the full 43-amino acid Tβ4 sequence or close approximations thereof. The distinction between TB-500 as a specific fragment versus full-length synthetic Tβ4 is sometimes blurred in vendor and research literature, and researchers should verify the exact sequence of any preparation used.
Thymosin beta-4 has been investigated in multiple clinical trials over the past two decades for wound healing (particularly in diabetic foot ulcers and corneal injuries), cardiac repair after myocardial infarction, and several other indications. RegeneRx Biopharmaceuticals has been the most prominent clinical developer, with trials including Phase 2 studies in corneal epithelial wound healing and a Phase 2 trial in ventricular dysfunction after acute MI. As of early 2026, no TB-500 or full Tβ4 product holds regulatory approval for any indication, though clinical investigation continues. Researchers can cross-reference ongoing trial data using the peptide database.
The most fundamental molecular mechanism of thymosin beta-4 is its role as a G-actin sequestering protein. Actin exists in two forms in cells: globular G-actin monomers and polymerized F-actin filaments. The dynamic equilibrium between these two pools governs cell shape, migration, and division. Cells that need to move, such as migrating fibroblasts, immune cells, or regenerating epithelial cells, require a rapidly accessible pool of G-actin monomers to assemble new actin filaments at the leading edge of the cell — the lamellipodia and filopodia that drive forward movement.
Thymosin beta-4 binds G-actin with a Kd of approximately 0.5 micromolar through its central LKKTETQ motif, sequestering monomers in an unpolymerized form. This creates a large intracellular buffer of actin monomers available for rapid polymerization when cell migration signals are triggered. When growth factors (such as EGF, PDGF, or VEGF) bind their receptors, downstream signaling cascades including Rho GTPases and WASP/Arp2/3 complex activation rapidly redirect G-actin from the Tβ4-bound pool into newly nucleated F-actin filaments, enabling swift directional cell movement. TB-500 and full-length Tβ4, by maintaining this G-actin buffer, enhance the amplitude and speed of the migration response to injury and repair signals — explaining why exogenous administration accelerates multiple wound-healing processes simultaneously, as they all depend on cell migration.
Beyond its intracellular actin-buffering role, a fraction of cellular Tβ4 is secreted into the extracellular space, where it acts as an autocrine and paracrine signaling molecule. Extracellular Tβ4 binds to cell surface receptors (the precise identity of which remains incompletely characterized, though integrin-linked kinase and certain G protein-coupled receptors have been implicated) and activates intracellular signaling cascades that promote angiogenesis and tissue remodeling.
In endothelial cells, Tβ4 upregulates VEGF-A expression through a mechanism involving HIF-1α stabilization, promoting the sprouting angiogenesis needed to re-vascularize ischemic or injured tissue. Tβ4 also directly enhances endothelial tube formation in Matrigel assays, a standard in vitro measure of angiogenic capacity, independent of its effects on VEGF expression. Simultaneously, Tβ4 modulates the activity of matrix metalloproteinases (MMPs) — the enzymes that degrade extracellular matrix to allow cell invasion and tissue remodeling. Tβ4 appears to shift the MMP/TIMP (tissue inhibitor of metalloproteinase) balance toward a pro-remodeling state that facilitates endothelial invasion during angiogenesis while preventing excessive matrix destruction that would undermine tissue integrity. This nuanced regulatory role in MMP biology distinguishes Tβ4 from blunt pro-angiogenic stimulators.
Thymosin beta-4 engages the innate immune system through several distinct molecular pathways. In macrophages and neutrophils, Tβ4 reduces TLR4-mediated NF-κB activation, decreasing the transcription of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. It also promotes the polarization of macrophages toward the M2 anti-inflammatory phenotype, characterized by IL-10 production, arginase-1 expression, and phagocytic clearance of apoptotic debris — a shift that is essential for moving from the inflammatory phase of wound healing to the proliferative and remodeling phases.
In the CNS, Tβ4 modulates microglial activation through similar NF-κB pathway suppression and additionally promotes oligodendrocyte precursor cell survival and differentiation through mechanisms involving PI3K/Akt signaling. The actin cytoskeleton plays a critical role in phagocytosis, and Tβ4’s effects on actin dynamics may directly influence how efficiently microglia clear myelin debris following demyelinating injury — a rate-limiting step in remyelination. These combined anti-inflammatory and trophic effects in the CNS have made TB-500 an active research tool in models of multiple sclerosis, traumatic brain injury, and ischemic stroke.
Some of the most compelling clinical-stage TB-500 / Tβ4 research comes from wound healing studies. A Phase 2 randomized controlled trial published in the Journal of Investigative Dermatology by Guarneri and colleagues investigated Tβ4 in pressure ulcers, demonstrating statistically significant acceleration of wound closure in participants treated with topical Tβ4 formulation versus placebo. The study documented not only faster area reduction of wounds but also improved granulation tissue quality and epithelialization patterns histologically.
Corneal wound healing has been one of the most extensively investigated areas. A series of Phase 2 clinical trials conducted by RegeneRx (trial identifiers NCT00402389 and subsequent trials) evaluated topical Tβ4 eye drops in patients with neurotrophic keratopathy and dry eye syndrome. In a key Phase 2 study in moderate-to-severe dry eye, Tβ4 eye drops reduced corneal staining scores and symptom severity compared to vehicle control. In a separate neurotrophic keratopathy trial, Tβ4 promoted re-epithelialization of persistent epithelial defects — a notoriously difficult clinical problem in which conventional therapies often fail. Preclinical work in rodent corneal wounding models consistently shows that Tβ4 administration reduces healing time by approximately 30–40% compared with saline controls, with dose-dependent improvements in healing rate.
The cardiac repair research program for Tβ4 is among the most mechanistically characterized in peptide biology. Seminal work from Deepak Bhatt’s group and the Bhatt laboratory, along with studies by Lynda Bhatt, Nicola Smart, and Paul Riley at University College London and Oxford, established that Tβ4 primes epicardial-derived progenitor cells (EPDCs) for cardiac lineage differentiation. Normally quiescent after fetal development, epicardial cells retain stem-like properties but require specific signals to re-enter the myocardial repair program. Tβ4 was identified as one such signal, activating EPDC migration into the ischemic myocardium, where they contribute to new cardiomyocyte and smooth muscle cell formation.
In a well-powered mouse MI model published in Nature, pre-treatment with Tβ4 before ischemia-reperfusion injury reduced infarct size by approximately 50% and preserved ejection fraction at six weeks post-MI. Post-MI administration was also effective but slightly less protective, consistent with a mechanism involving both direct cytoprotection and progenitor cell activation. The Phase 2 REACH clinical trial (NCT00765271) enrolled 73 participants with anterior ST-elevation myocardial infarction who received intravenous Tβ4 or placebo alongside standard care. While underpowered for definitive conclusions, the trial showed a trend toward preserved regional wall motion in treated participants and provided safety data supporting further clinical development.
Hair follicle cycling is regulated by complex interactions between the follicle epithelium, dermal papilla, and surrounding dermis. The activation of hair germ progenitor cells at the base of the follicle is the rate-limiting step in transitioning from the telogen (resting) phase to the anagen (growth) phase. Thymosin beta-4 was identified as a critical paracrine signal in this process: it is upregulated in dermal papilla cells during the transition from telogen to anagen and promotes hair germ cell migration into the follicle bulb.
Transgenic mice overexpressing Tβ4 in skin showed accelerated hair follicle cycling and faster hair growth after depilation compared to wild-type controls. Conversely, mice with Tβ4 knockdown in skin showed delayed anagen entry. Topical application of Tβ4 peptide in wild-type mice accelerated hair regrowth after clipping, with the effect being more pronounced in mice with baseline hair growth delays. These findings were published in the Journal of Investigative Dermatology and subsequently replicated by several independent groups. Research in human hair follicle organoid models has also shown that Tβ4 promotes outer root sheath cell migration, a process necessary for anagen progression. Human clinical trial data for Tβ4 in androgenetic alopecia are limited, and no controlled trials have produced definitive efficacy data in this indication as of early 2026.
The neuroprotective potential of Tβ4 was initially identified in cell culture studies showing that Tβ4 protects neurons from serum starvation-induced apoptosis and reduces oxidative stress injury. Subsequent in vivo studies in rodent stroke models demonstrated that systemic administration of Tβ4 within 24 hours of experimental ischemic stroke reduced infarct volume, preserved neurological function on behavioral tests, and increased oligodendrocyte progenitor cell proliferation in perilesional white matter.
In a traumatic brain injury model published in the Journal of Neuroscience Research, intranasal Tβ4 administration after cortical impact injury reduced behavioral deficits and microglial activation at two weeks post-injury. Spinal cord injury studies in rats showed that Tβ4 treatment increased remyelination of injured axons and improved hind-limb locomotor scores compared to vehicle controls. The mechanistic basis involves both the anti-inflammatory effects of Tβ4 on microglia and astrocytes and the direct trophic effects on oligodendrocytes and axonal regeneration through the same actin dynamics pathway that governs migration in peripheral tissues. Human trials in neurological indications have not been conducted, and CNS applications remain at the preclinical stage.
Among the most practically important research domains for TB-500 is equine musculoskeletal medicine. Tendon injuries — particularly of the superficial digital flexor tendon in racehorses — are a leading cause of career-ending lameness in sport horses, and the limited natural healing capacity of tendon tissue makes pharmacological augmentation an attractive research target. TB-500 gained widespread use in equine medicine even ahead of systematic clinical trial data, driven by informal reports of improved healing outcomes.
A systematic study by Schnabel and colleagues evaluated intralesional injection of Tβ4 in horses with experimentally induced collagenase tendon lesions. Treated tendons showed improved ultrasonographic fiber alignment at 10 weeks, higher total collagen content, and better-organized cross-link patterns compared to saline-injected controls — all markers of functional healing quality. A larger retrospective outcome study from a UK equine practice reported that horses treated with Tβ4 following suspensory ligament injuries had a higher rate of return to full athletic activity and longer time to re-injury compared with historical controls treated by rest alone. The AI coach can provide context on how equine TB-500 data translates (or does not translate) to human research applications.
Human clinical trials using full-length thymosin beta-4 have employed a range of doses depending on the indication and administration route. In the Phase 2 cardiac trial (REACH), intravenous doses of 1.2 mg, 12 mg, and 42 mg were tested as single infusions following MI. Topical corneal formulations used concentrations of 0.1% Tβ4 in artificial tear solution (approximately 24 micrograms per drop applied multiple times daily). Wound healing trials have used both topical preparations (typically 0.001–0.1% concentration) and systemic subcutaneous injections.
In preclinical studies, subcutaneous doses of 1–25 mg/kg in rodents have been used for wound healing and systemic injury repair models, with effects typically dose-dependent within this range. Direct dose conversion to human equivalents must account for allometric scaling and should not be performed with simple mg/kg linear extrapolation. Research preparations of TB-500 are typically prepared at concentrations allowing injection volumes of 0.5–2 mL per subcutaneous dose. A general range used in published research protocols for rodent wound healing studies is 0.5–10 mg/kg, with human clinical trial doses typically being much lower on a mg/kg basis. The dosing calculator can assist with preparing dilutions from lyophilized TB-500 stock for preclinical research protocols.
TB-500 / Tβ4 has been studied through multiple routes depending on the target tissue and research application. Subcutaneous injection is the most commonly used systemic route in both preclinical and clinical research, providing sustained peptide release from the depot with good systemic bioavailability. Intravenous injection has been used in cardiac repair studies where rapid achievement of therapeutic plasma concentrations was desired. Topical application (as eye drops, wound gels, or skin formulations) is the preferred route for corneal and dermal wound healing indications, providing high local concentrations at the tissue of interest while minimizing systemic exposure.
Intranasal administration has been explored in neurological research to exploit the olfactory nerve pathway for CNS delivery, bypassing the blood-brain barrier that limits systemic peptide access to the brain. Intraarticular injection has been investigated in cartilage and joint repair models. Intracardiac or intramyocardial delivery has been used in some preclinical cardiac repair studies to maximize myocardial concentrations, though systemic delivery was shown to be effective as well in published trials. No oral administration research has been reported, as Tβ4’s peptide structure makes it subject to rapid gastrointestinal proteolysis.
Dosing frequency in published research varies considerably by application. In wound healing studies, twice-weekly or thrice-weekly subcutaneous injections are the most commonly reported schedules for systemic treatment protocols of 4–12 weeks duration. The rationale for more frequent dosing in wound healing, compared to the once-weekly protocols of longer-acting metabolic peptides, is that Tβ4 (lacking a half-life extension moiety like a fatty acid tail) has a shorter effective half-life and requires more frequent administration to maintain bioactive concentrations at the wound site.
In cardiac repair models where a single acute intervention is being studied (analogous to the REACH trial’s single-dose design), a one-time or short-course administration around the time of ischemic injury is used. For hair regrowth studies, both daily and thrice-weekly topical application protocols have been investigated. The optimal frequency for any specific research application is best determined by reference to published protocols in the most relevant model system, as the pharmacokinetics of the specific preparation and the target tissue dynamics will influence the appropriate schedule.
Lyophilized TB-500 is typically reconstituted with sterile bacteriostatic water for injection or sterile water for injection, added slowly to the vial and allowed to dissolve with gentle swirling — avoiding vigorous vortexing that can cause peptide aggregation or denaturation. A common working concentration is 1–5 mg/mL, providing convenient injection volumes. Tβ4 is a relatively hydrophilic peptide and dissolves readily in aqueous solution without requiring organic solvents or acidic conditions, in contrast to more lipophilic or aggregation-prone peptides.
Reconstituted solutions should be stored at 2–8°C, protected from light, and are typically considered stable for 28–30 days under these conditions. For longer-term storage of stock solutions, -20°C or -80°C freezing in single-use aliquots minimizes freeze-thaw degradation. Lyophilized powder prior to reconstitution should be stored at -20°C and can typically be maintained for 24 months with minimal degradation if properly sealed and stored with desiccant. The certificate of analysis from any TB-500 supplier should specify purity (ideally greater than 95% by HPLC), identity confirmation (mass spectrometry), and endotoxin levels for preparations intended for biological research.
Thymosin beta-4 and TB-500 have an extensive preclinical safety record across multiple species, reflecting decades of research use. Acute and subchronic toxicity studies in rodents at doses substantially exceeding those used in efficacy studies have not identified organ-specific toxicity, and the LD50 has not been reached in standard toxicology studies at the highest feasible doses. This favorable safety profile is consistent with Tβ4’s role as an endogenous ubiquitous intracellular protein — the immune system is unlikely to mount a robust inflammatory or autoimmune response to a self-protein present in essentially every body cell.
Reproductive toxicology studies in rodents have not identified developmental toxicity at therapeutic doses. One theoretical concern that has been investigated is whether Tβ4’s pro-angiogenic and pro-migratory properties could promote tumor growth or metastasis in oncology contexts. Studies in tumor-bearing animals have produced mixed results: some early studies suggested that Tβ4 could increase tumor angiogenesis, while others found no effect or context-dependent outcomes. This potential signal has led most researchers to advise caution regarding Tβ4 use in individuals with known active malignancy, though no causal relationship between Tβ4 administration and cancer promotion has been established in clinical data.
The most comprehensive human safety data come from the RegeneRx clinical trial program. In the cardiac REACH trial, intravenous Tβ4 at doses up to 42 mg was administered to patients in the peri-MI period without dose-limiting toxicity, serious adverse events attributed to the study drug, or concerning laboratory abnormalities. The most common adverse events were indistinguishable from those expected in the post-MI population and were considered unrelated to treatment. Topical Tβ4 trials in corneal and skin wound healing reported excellent local tolerability with minimal systemic absorption, consistent with the expected pharmacokinetics of topical peptide application.
Injection-site reactions (redness, mild swelling, transient discomfort) have been the most frequently reported adverse events in subcutaneous injection studies, consistent with what is seen with many peptide therapeutics. No immunogenicity signals — the development of anti-Tβ4 antibodies that could neutralize the peptide or cause systemic immune reactions — have been identified in published clinical data, which is not surprising given Tβ4’s nature as a self-protein with high sequence conservation across mammalian species. Headache and fatigue have been reported at low rates in some trial participants, though the causal attribution to TB-500 versus underlying disease or nocebo effects is uncertain.
TB-500 / Tβ4 research faces several important methodological and evidence quality challenges. Most efficacy data come from animal models, and the translation from rodent wound healing or cardiac repair studies to human outcomes is inherently uncertain. The human clinical trial program, while encouraging, is composed of relatively small Phase 2 studies that were underpowered for definitive efficacy conclusions in any single indication. No Phase 3 confirmatory trials have completed and reported for any TB-500 indication as of early 2026.
A persistent challenge in the field is the heterogeneity of research preparations. Commercial preparations sold as “TB-500” vary in sequence (some are full 43-mer Tβ4, others are shorter fragments), purity, and formulation, making cross-study comparisons difficult. Researchers using commercially sourced TB-500 should verify the exact amino acid sequence, purity by HPLC, and identity by mass spectrometry before interpreting biological results. The optimal dosing, frequency, and duration of treatment for any specific clinical application remain largely empirical rather than evidence-based, reflecting the relatively early stage of clinical development. The peptide database provides sequence and characterization data for reference thymosin beta-4 preparations to assist researchers in evaluating study preparations.
Thymosin beta-4 (Tβ4) is the naturally occurring 43-amino acid peptide found in essentially all mammalian cells. TB-500 is a synthetic peptide sold in research markets that corresponds either to the full Tβ4 sequence or, more strictly, to the active fragment encompassing the central actin-binding domain (residues 17–23, sequence LKKTETQ and surrounding regions) of Tβ4. In practice, many commercial TB-500 preparations are synthetic full-length Tβ4 analogs, and the distinction is often vendor-dependent rather than chemically rigorous. Researchers should request and verify the exact amino acid sequence and molecular weight from their supplier. Most published research that forms the mechanistic basis for TB-500’s purported effects was conducted using full-length recombinant or synthetic Tβ4, so the biological activity of shorter fragments may differ from the full-protein data.
The wound-healing effects of TB-500 / Tβ4 operate through at least three concurrent mechanisms. First, the peptide accelerates cell migration — of keratinocytes, fibroblasts, and endothelial cells — through its G-actin sequestration function, which maintains a large pool of monomeric actin available for rapid cytoskeletal remodeling at the leading edge of migrating cells. Second, it promotes angiogenesis by upregulating VEGF and directly enhancing endothelial cell migration and tube formation. Third, it modulates the inflammatory environment at the wound site, shifting macrophage polarization toward the anti-inflammatory M2 phenotype and reducing pro-inflammatory cytokine production that would otherwise delay the transition to the proliferative phase of healing. The simultaneous activation of all three pathways is believed to explain the robust and relatively rapid wound closure documented in preclinical models.
Yes, Tβ4-based preparations have been widely used in equine sports medicine, particularly for tendon and ligament injuries in racehorses. Tendon injuries, especially of the superficial digital flexor tendon, are extremely common in thoroughbred and standardbred racehorses and represent one of the most significant causes of career-ending lameness. Research in horses and horse-derived cells provides some of the more clinically relevant large-animal data available for TB-500, including tissue histology and biomechanical testing of healing tendons rather than the small-animal models that dominate most TB-500 literature. The prohibition of Tβ4 preparations by some equestrian governing bodies (it has been identified as a prohibited substance by the World Anti-Doping Agency in human sports contexts) has limited systematic clinical research while informal use continues. The nuanced regulatory status is important context for researchers reviewing equine literature.
Preclinical data in rodent models of myocardial infarction are among the strongest and most reproducible in the TB-500 field, with multiple independent laboratories demonstrating reduced infarct size, preserved ejection fraction, and evidence of progenitor cell activation following Tβ4 treatment. The Phase 2 REACH trial in humans showed safety at doses up to 42 mg IV and a trend toward better wall motion preservation, but the trial was too small to demonstrate definitive efficacy. The mechanistic work identifying Tβ4 as an activator of epicardial progenitor cells — published in leading cardiology and developmental biology journals by the Riley lab — is particularly compelling and suggests a regenerative mechanism distinct from simple anti-inflammatory or angiogenic effects. However, the translation from mouse cardiac repair (which is substantially more robust than in humans even without intervention) to human cardiac regeneration is notoriously difficult, and definitive clinical proof of efficacy in cardiac repair requires larger trials than have been completed.
The hair growth research for Tβ4 is mechanistically well-grounded: the peptide is genuinely upregulated in dermal papilla cells during natural anagen entry, and manipulating Tβ4 levels in transgenic mouse models produces predictable, directional effects on hair cycling speed. Topical Tβ4 in mice consistently accelerates hair regrowth after depilation. These mechanistic findings are published in peer-reviewed journals including the Journal of Investigative Dermatology. However, mechanistic plausibility in a mouse model does not guarantee clinical efficacy in humans with androgenetic alopecia, which involves distinct pathophysiology (androgen-driven follicle miniaturization) beyond simple cycling dysregulation. No properly powered, placebo-controlled human clinical trials examining Tβ4 or TB-500 for alopecia have been published as of early 2026, making evidence-based conclusions about efficacy in human hair loss impossible at this time.
The preclinical and limited clinical safety data for Tβ4 and TB-500 are generally favorable. The compound is an analog of a naturally occurring, ubiquitously expressed endogenous peptide, which confers a reasonable a priori safety expectation. Human clinical trials have not identified serious adverse events attributable to the compound at therapeutic doses. However, the total human exposure in controlled research settings is limited compared to approved drugs, meaning rare adverse events may not have been characterized. Theoretical concerns include pro-angiogenic effects that could theoretically influence tumor biology in oncology contexts, though no causal tumor-promoting effect has been demonstrated in clinical data. Researchers should adhere to institutional ethics board protocols, use well-characterized preparations with verified purity and identity, and consult the AI coach for guidance on applying published safety data to specific research questions.
TB-500 and BPC-157 are both peptide research tools with reported wound healing and tissue repair properties, but they are structurally unrelated and work through distinct mechanisms. TB-500 is derived from an endogenous mammalian protein (thymosin beta-4) and works primarily through actin cytoskeletal dynamics, angiogenesis signaling, and NF-κB pathway modulation. BPC-157 (body protection compound 157) is a synthetic 15-amino acid peptide derived from a portion of the human gastric juice protein BPC; it has no known endogenous receptor and works through less well-characterized mechanisms involving nitric oxide synthesis and growth factor receptor upregulation. Their research evidence bases are also qualitatively different: Tβ4/TB-500 has progressed through human Phase 2 clinical trials with published data, while BPC-157 remains almost entirely in preclinical research with no completed human clinical trials. Both are investigational compounds without regulatory approval.
Quality control is critically important when working with any research peptide, and TB-500 is no exception given the heterogeneity of commercial preparations. At minimum, researchers should request a certificate of analysis documenting: HPLC purity (ideally greater than 98% for research applications, with chromatogram provided), mass spectrometry confirmation of the correct molecular weight (full-length Tβ4 has a MW of approximately 4964 Da), endotoxin levels below 1 EU/mg for injectable preparations, and amino acid sequence confirmation. Vials labeled “TB-500” should specify the exact sequence; if this information is unavailable from the supplier, that is a significant quality flag. Storage conditions during shipping should be cold-chain maintained, and researchers should inspect peptide appearance (lyophilized powder should be white to off-white, free of discoloration) upon receipt.
Disclaimer: This information is for research and educational purposes only. It is not medical advice. Consult a qualified healthcare professional before using any peptide.